Advancements in EGFR-Mutant NSCLC: ADCs and Other Targeted Therapies
Learn about the latest developments in the treatment of lung cancer, focusing on EGFR mutations, antibody-drug conjugates (ADCs), targeted therapies, and biomarker-driven approaches to improve patient outcomes in various stages of the disease.
EP: 1.Biomarker Testing and Advancements in EGFR-Mutant NSCLC Treatment Strategies
EP: 2.Revolutionizing First-Line Strategies in EGFR-Mutant NSCLC: Combination Therapies
EP: 3.Impact of Combination Therapies and CNS Efficacy in EGFR-Mutant NSCLC Treatment
EP: 4.EGFR-Mutant NSCLC: Second-Line Treatment Options and Safety Data
Now Viewing
EP: 5.Advancements in EGFR-Mutant NSCLC: ADCs and Other Targeted Therapies
EP: 6.EGFR Exon 20 Insertion NSCLC: A Comprehensive Overview
EP: 7.Unmet Needs in EGFR Exon 20 Insertion Non–Small Cell Lung Cancer
EP: 8.“Exciting Year” for Targeted Therapy Options for Mutated NSCLC, Experts Say
Recent Videos
